# Tuesday, November 25, 2008
The Securities and Exchange Commission (SEC) is quickly changing regulations to encourage transparency for individual investors. Several accounting changes are under review, including mark-to-market, while the commission continues to prosecute insiders involved with fraud. However, the recent move to eliminate paper filings and require electronic filings may usher in a whole new era of transparency for both public and private investors in the United States.

The private sector changes will primarily be seen in the required electronic filing for Regulation D. This controversial filing provides three exemptions from the Securities Act registration. These exemptions allow reporting companies to receive investment in private markets without having to report it as a registration. Further, the filings themselves (which do contain the information) can be concealed by filing it in paper form (so an interested investor would have to obtain a mailed copy from the SEC!).

Times are changing, however, and the SEC is set on increasing financial transparency. The SEC allowed companies to make electronic Regulation D filings this year, but this ability will turn into a requirement next year. This will not only allow visibility into the VC markets but also change a hedge fund strategy that has been built around this secrecy. This is good news for investors who will now be able to see private transactions in the companies they own without hassel.

However, the SEC also took a step backwards with the transparency. The new Regulation D form requires less information than the original. The removed information includes the names of significant shareholders and the specific type of security. So, while the financial terms are disclosed, information about the related parties are withheld. This was likely designed to protect hedge funds and other private investors who value their privacy from the public eye.

Investors are now being given access to the big picture, but it has been broken down into a puzzle...

Tuesday, November 25, 2008 4:31:33 PM UTC  #     |  Trackback
# Monday, November 24, 2008
Orange 21 Inc. (NDAQ: ORNG) shares opened lower after Costa Brava withdrew its $3.90 per share aquisition offer. Many investors are attributing this withdrawal to the poor financing environment that may prohibit anything but an all-cash deal. In fact, Orange 21 even reported a net income of $6,000 for the quarter compared to a loss of $58,000 during the prior year quarter. Consolidated net sales declined, however, to $12 million from $13.2 million. The benefits came from lower operating expenses.

According to the Schedule 13D/A filing made with the SEC:
"On November 21, 2008, Costa Brava sent a letter to the Board of Directors of the Issuer withdrawing its proposal to acquire 100% of the outstanding equity interests of the Issuer. A copy of the letter delivered to the Issuer is filed as Exhibit B hereto and is incorporated herein by reference.

The Reporting Persons believe that the shares of Common Stock of the Issuer are undervalued and they are considering pursuing any and all of the actions enumerated below.

The Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation: (i) having communications with the Issuer's Board of Directors and management with respect to methods for increasing stockholder value; (ii) purchasing additional shares of Common Stock in the open market or otherwise; and (iii) making a tender offer for shares of Common Stock not owned by the Reporting Persons.

The Reporting Persons may also participate in discussions with potential purchasers of their shares of Common Stock, sell some or all of their shares of Common Stock in the open market or through private negotiated transactions, or change their intent as to any and all matters referred to above.

The Reporting Persons reserve their rights to make alternative plans or proposals in the future or to take other steps to enhance the value of their investments. The Reporting Persons further reserve the right to increase, decrease or eliminate their investment in the Issuer or take any other action relative thereto."
Related Companies
FGX International Holdings Limited (FGXI)
Luxottica Group S.p.A. (LUX)
Shamir Optical Industry Ltd. (SHMR)

Monday, November 24, 2008 6:41:53 PM UTC  #     |  Trackback
# Friday, November 21, 2008
Enzon Pharmaceuticals, Inc. (NDAQ: ENZN) shares moved higher after a large investor disclosed that they hired an advisor to explore strategic alternatives for the company in a Schedule 13D filing with the SEC. DellaCamerca Capital Master Fund engaged the investment banking firm Moelis & Company LLC to explore strategic alternatives with respect to the investment in the company. The 7.8% shareholder is likely attempting to find a buyer to boost the share price.

Last quarter, Enzon reported strong results and a net loss of just $2 million or $0.05 per share. The third quarter results were impacted by the $88.7 million net gain from the sale of a portion of their PEG-INTRON royalty asset. All in all, the company remains strong and continues to see growth and stability in their marketed products. Unfortunately, the volatile external markets impacted the ability to complete the sale of their specialy businesses at this time, however.

The strategic transactions that Enzon is already undertaking represents an effort to unlock value while many of its shareholders also continue to explore ways to maximize their investment. The result has been a stock in decline so far but opportunity in the near future. Shares of the pharmaceutical firm rose $0.08, or 1.86%, to $4.38 per share on the day.

Related Companies
Nektar Therapeutics (NKTR)
Gilead Sciences Inc. (GILD)
Johnson & Johnson (JNJ)

Friday, November 21, 2008 8:12:28 PM UTC  #     |  Trackback